SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The sales is pegged at Rs. 114.61 millions for the March 2023 quarter. The mentioned figure indicates a decline of about -40.18% as against Rs. 191.58 millions during the year-ago period.The Net Loss for the quarter ended March 2023 is Rs. -69.39 millions as compared to Net Loss of Rs. -113.15 millions of corresponding quarter ended March 2022 Operating profit Margin for the quarter ended March 2023 improved to -44.31% as compared to -89.86% of corresponding quarter ended March 2022


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202303 202203 % Var 202303 202203 % Var 202303 202203 % Var
Sales 114.61 191.58 -40.18 521.34 597.03 -12.68 521.34 597.03 -12.68
Other Income 1.93 7.93 -75.66 6.20 11.56 -46.37 6.20 11.56 -46.37
PBIDT -44.31 -89.86 -50.69 -151.59 -328.39 -53.84 -151.59 -328.39 -53.84
Interest 10.28 2.80 267.14 29.73 53.91 -44.85 29.73 53.91 -44.85
PBDT -54.59 -92.66 -41.09 -181.32 -382.30 -52.57 -181.32 -382.30 -52.57
Depreciation 14.80 20.49 -27.77 65.59 62.97 4.16 65.59 62.97 4.16
PBT -69.39 -113.15 -38.67 -246.91 -445.27 -44.55 -246.91 -445.27 -44.55
TAX 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Deferred Tax 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
PAT -69.39 -113.15 -38.67 -246.91 -445.27 -44.55 -246.91 -445.27 -44.55
Equity 215.61 215.61 0.00 215.61 215.61 0.00 215.61 215.61 0.00
PBIDTM(%) -38.66 -46.90 -17.57 -29.08 -55.00 -47.14 -29.08 -55.00 -47.14

Krebs Biochem.&Inds Share Price

60.90 -0.12 (-0.20%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×